CONMED Non-GAAP EPS of $1.04 beats by $0.04, revenue of $335.6M misses by $0.65M (CNMD:NYSE)

CONMED reported Q3 Non-GAAP EPS of $1.04, beating estimates by $0.04, but revenue of $335.6M missed expectations by $0.65M. The company updated its full-year 2026 financial guidance based on Q3 performance and outlook.

Original reporting
Published Oct 28, 2026, 8:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CNMD
Bullish
high confidence
Mentioned
$CNMD
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$CNMDBullishHigh
01

Why it matters

The earnings release is the primary source of new information, making it highly relevant for short‑term traders.

02

Market read

First‑report earnings data for a U.S.-listed healthcare company; actionable for traders evaluating post‑earnings moves.

03

What to watch

Management's updated full‑year guidance may contain upside potential not reflected in the brief excerpt.

Relevance 8/10Novelty 8/10Timing: after-hours release

Background

CONMED released its Q3 2026 earnings, providing the first public disclosure of the quarter's results and an update to full‑year guidance.

Company-level read

Ticker impact

$CNMDBullishHigh confidence
Context

Q3 non‑GAAP EPS of $1.04 beat expectations by $0.04, while revenue of $335.6M missed by $0.65M and guidance was updated.

Expected impact

modest downside pressure as the revenue miss offsets the EPS beat

Evidence & confidence

Investors often prioritize revenue trends; a miss, even small, can trigger sell pressure despite a modest EPS beat.

Market effects

Medical device sector may see slight scrutiny on revenue growth trends.

U.S. small‑cap healthcare stocks could experience modest volatility.

Limited to investors tracking U.S. healthcare equities.

Counterpoint

The EPS beat could signal underlying profitability strength, suggesting a buying opportunity despite the revenue miss.

Key entities

  • CONMED Corporation

    Medical device manufacturer reporting Q3 results.

Related articles

$CNMDMedAI 8/10

CNMD Q3 deep dive: stable revenue, margin improvement, and focus on core growth platforms

CONMED reported Q3 revenue of $335.6M, matching estimates, with adjusted EPS of $1.04, beating estimates by 3.7%. Adjusted EBITDA was $67.88M, a 2.9% beat. The company reconfirmed revenue guidance of $1.36B and raised adjusted EPS guidance to $4.58. Operating margin improved to 11.1%. International sales and AirSeal platform growth drove performance, while U.S. orthopedic sales declined.

$CNMDMed

Conmed Corp (CNMD) Q3 2026 Earnings Call Highlights: Solid Organic Growth Offset

Conmed Corp (CNMD) reported Q3 2026 earnings with global general surgery up 6.4% and orthopedics up 7.2%. U.S. general surgery grew 2%, while U.S. orthopedics declined slightly. CEO Pat Beyer highlighted strong performance in AirSeal and direct smoke evacuation, but noted variability in OEM business. CFO John Gallagher adjusted the organic growth range to 5.5% due to international performance. AirSeal grew in high single-digit to low double-digit range.

$CNMDHighAI 8/10

CONMED Q3 Earnings Call Highlights

CONMED reported Q3 organic revenue growth of 7.2% in orthopedic surgery, driven by international demand and BioBrace. Adjusted gross margin increased to 56.4%. The company updated its 2026 outlook, narrowing revenue growth to 5%-5.5% and raising adjusted EPS guidance to $4.54-$4.61. CONMED repurchased 1.2 million shares and expects to allocate $62 million to buybacks for the year.

$CNMDMed

CONMED (CNMD) Q3 2026 Earnings Call Transcript

CONMED (CNMD) reported Q3 2026 net revenue of $335.6M, with organic growth of 6.7% YoY. Adjusted EPS was $1.04, exceeding expectations. AirSeal and Buffalo Filter drove sales growth, with AirSeal showing strong performance in robotic and laparoscopic surgery. The company remains optimistic about long-term growth prospects for these products.

$CNMDMedAI 8/10

Conmed (CNMD) Q3 Earnings Top Estimates

Conmed (CNMD) reported Q3 earnings of $1.04 per share, beating estimates by $0.04. Revenue was $335.56M, missing estimates by 0.37%. The company has beaten EPS estimates four times in the last four quarters. Shares are up 16.3% YTD. The Zacks Rank for the stock is #3 (Hold).